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Identity 
Other names: KIAA0978, MGC117280, MGC71111 
HGNC (Hugo): ASXL1 
Location: 20q11.21 
Local order: centromere 5' - 3' telomere. 
 
Representation of ASXL1 locus. A: Chromosome 20 with localisation of ASXL1; B: ASXL1 gene; C: Amino acid count; D: Protein with 
domains. ASXN, conserved domain at the N-terminus; ASXM, conserved domain in the middle part; NR, nuclear receptor; PHD, plant 
homeodomain; E: examples of mutations. 
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DNA/RNA 
Description 
The ASXL1 gene spans around 80 kb of genomic DNA 
and is composed of 12 exons. 
Transcription 




The longer ASXL1 transcript encodes a 1541 amino 
acid (170 kDa) protein. Mammalian ASXL proteins are
characterized by an amino-terminal ASX homology 
(ASXH) region containing 2 putative nuclear receptor 
coregulator binding motifs (NR box), 3 other NR box 
motifs and a C-terminal plant homeodomain protein-
protein interaction domain. Contains one Leu-Xaa-Xa-
Leu-Leu (LXXLL) motif, which may be required for an 
association with nuclear receptors. 
Expression 
ASXL1 is expressed all hematopoietic cell fractions i  
mice. Asxl1 knockout mice exhibit mild defects in 
differentiation of lymphoid and myeloid progenitors, 
but not in multipotent progenitors and do not develop 
MDS or other hematological malignancy. 
ASXL1 is widely expressed at low level in heart, brain, 
skeletal muscle, placenta, pancreas, spleen, prostate, 
small intestine, colon, peripheral blood, leukocytes, 




- ASXL1 acts as a co-regulator of retinoic acid (RA) 
receptor in RA sensitive cell lines, and as a co-
repressor of RA receptor in RA resistant cell lines. 
Either a coactivator or corepressor for the retinoid 
receptors retinoic acid receptor and retinoid X receptor 
in a cell type-specific manner. 
- ASXL1 cooperates with HP1 (heterochromatin 
protein 1) to modulate histone H3 demethylase LSD1 
activity, leading to a change in histone H3 methylation 
and RAR repression. 
- ASXL1 belongs to the Enhancer of Trithorax and 
Polycomb (ETP) group in drosophila. 
- ASXL1 is required for maintenance of both activation 
and silencing of Hox genes in mice and drosophila in 
context-dependent manner. 
- ASXL1 is one of the fusion protein partners of PAX5 
in B-cell precursor acute lymphoblastic leukemias. 
- ASXL1 may function as a tumor suppressor in 
myeloid malignancies by affecting stem or progenitor 
cell self renewal or differentiation. 
Homology 
There are 3 mammalian homologs of the Additional sex 
combs (Asx) gene of Drosophila: ASXL1, 2 
(chromosome 2p24 in humans) and 3 (chromosome 
18q11 in humans). 
Mutations 
Note 
Acquired ASXL1 mutations are frequently frameshift 
and nonsense. All mutations are in exon 12, mostly 
around the Gly-rich domain (amino acids 642-685). 
The most common somatic mutation is 
p.Gly646Trpfsx12. 
These mutations cause truncation of the ASXL1 protein 
downstream of the ASXH domain leading to the loss of 
the C-terminal PHD domain. 
Some possible single nucleotide polymorphisms have 
been described:  
p.Arg1224Thr, p.Thr769Ala, p.Gly1007Arg, 
p.Thr688Met, p.Gln1074Leu, p.Arg693Gly, p.T1139K, 
p.Gly652Ser, p.Val1072Asp... 
All mutations have been found in myeloid diseases so 
far. A fusion has been found in B-cell leukemia. 
Implicated in 
Myelodysplastic syndromes (11-21%) 
Note 
Mutations p.Arg596Profsx23, p.Gly646Trpfsx12 (the 
most common mutation), p.Gln1102Asp, 
p.Leu1395Val, p.Ser1457Profsx18... 
Prognosis 
More frequent in advanced and high-risk MDSs (>40% 
in RAEB2). 
Cytogenetics 
Normal or abnormal karyotype. 
Chronic myelomonocytic leukemia (33-
43%) 
Note 
p.His630Profsx66, p.Lys618X, p.Gly646trpfsx12, 
p.Gln768X, p.Thr836Leufsx2, p.Ser846Glnfsx5, 
p.Lys888Glufsx6, p.Arg1068X, p.pro1263Glnfsx17, 
p.Leu1266Hisfsx9, p.Thr1271lysfsx10... 
Prognosis 
Associated with acute transformation. 
Cytogenetics 
Normal or abnormal karyotype. More common in 
patients with -7/7q-. Infrequent in the presence of -
5/5q-. 
Juvenile myelomonocytic leukemia 
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Cytogenetics 
Normal karyotype or monosomy 7. 
Acute myeloid leukemia (20-30%) 
Note 
30% in primary AMLs, 47% in secondary AMLs and 
23% in post-MDS AMLs. 
Prognosis 
Shorter overall survival. 
Cytogenetics 
Normal or abnormal karyotype, associated with trisomy 
8, inversely correlated with NPM1 mutation. 
Myeloproliferative neoplasms (8%) 
Note 
Present in all forms, including chronic myeloid 
leukemia. More frequent in primary myelofibrosis. 
Prognosis 
Occur in both chronic and blast-phase MPNs. 
B-cell acute lymphoblastic leukemia 
Cytogenetics 
Dicentric chromosome dic(9;20)(p11-13;q11). 
Hybrid/Mutated gene 
PAX5 on 9p and ASXL1 on 20q. 
To be noted 
Note 
ASXL1 can be altered by small local deletion detected 
only by array CGH or SNP arrays. However, ASXL1 
seems to be centromeric to the main deleted region in 
classical 20q deletion. 
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